海正药业参股子公司博锐生物向香港联交所递交上市申请

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its associate company, Zhejiang Borui Biopharmaceutical Co., Ltd. (Borui Biopharma), has submitted an application for an initial public offering (IPO) of H-shares on the Hong Kong Stock Exchange on January 6 [2]. Group 1 - Haizheng Pharmaceutical holds a 39.62% stake in Borui Biopharma as of the announcement date [2]. - The IPO application materials were published on the Hong Kong Stock Exchange website on the same day [2].